|
|
|
Volumn 1, Issue 11, 2003, Pages 679-684
|
|
Optimizing the management of chemotherapy-induced neutropenia.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
HEMOPOIETIC GROWTH FACTOR;
RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;
CHEMICALLY INDUCED DISORDER;
CLINICAL TRIAL;
DELAYED RELEASE FORMULATION;
DISEASE MANAGEMENT;
DISEASE PREDISPOSITION;
DOSE RESPONSE;
DRUG ADMINISTRATION;
ECONOMICS;
FEVER;
HUMAN;
INFECTION CONTROL;
NEOPLASM;
NEUTROPENIA;
QUALITY OF LIFE;
REVIEW;
RISK ASSESSMENT;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS;
DELAYED-ACTION PREPARATIONS;
DISEASE MANAGEMENT;
DISEASE SUSCEPTIBILITY;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
FEVER;
FILGRASTIM;
HEMATOPOIETIC CELL GROWTH FACTORS;
HUMANS;
INFECTION CONTROL;
NEOPLASMS;
NEUTROPENIA;
QUALITY OF LIFE;
RISK ASSESSMENT;
|
|
EID: 13844277525
PISSN: 15430790
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (10)
|
|
References (67)
|
